Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen

Malaria Clinical Trial

Official title:

Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Virosomal Vaccine PEV3A and FP9-MVA ME-TRAP. A Phase I / IIa Controlled Challenge Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00408668
• Other study ID #: VAC030
• Secondary ID: MRC agreement ID
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: December 5, 2006
• Last updated: December 5, 2006
• Start date: August 2005
• Est. completion date: February 2006

Study information

• Verified date: October 2006
• Source: University of Oxford
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test three candidate malaria vaccines in new combinations to assess their efficacy at preventing malaria infection and triggering immune responses against malaria.

Description:

Two of the vaccines (‘FP9 ME-TRAP’ and ‘MVA ME-TRAP’) have been designed at the University of Oxford. The other vaccine (PEV3A) has been designed jointly between the Swiss Tropical Institute and a Swiss company called Pevion Biotech Ltd. These are new vaccines that have been given to only a limited number of people before.

We aim to test these vaccines by:

• assessing their ability to prevent malaria infection

• determining how good they are at triggering a detectable immune response against malaria

• studying their safety further

Volunteers will be given up to six vaccinations over three months and will then be exposed to malaria infection. We do this by allowing mosquitoes infected with malaria to bite them under closely regulated conditions and observing if and when they develop blood stage malaria. If the vaccines provide some protection from malaria infection then either they will not develop malaria after the bites or the time taken to develop malaria will be longer. If not all volunteers are protected then we will be able to try and improve our vaccines by comparing the immune responses of volunteers who are protected to those not protected.

The information we get from this study may help to prevent malaria infection and disease in those who live in endemic areas and in travellers. The results of this study will be published in scientific journals and may be presented at professional meetings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: February 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Healthy adults aged 18 to 50 years

• Written informed consent

• Resident in or near Oxford for the duration of the vaccination study

• For women only, willingness to practice continuous effective contraception during the study and (if participating) during the subsequent challenge study.

• Agreement to refrain from blood donation during the course of the study

• Willingness to undergo an HIV test

Exclusion Criteria:

• Any deviation from the protocol defined normal range in biochemistry or haematology blood tests or in urine analysis

• Prior receipt of an investigational malaria vaccine

• Use of any investigational or non-registered drug, vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period

• Administration of chronic immunosuppressive drugs or other immune modifying drugs within six months of vaccination.

• History of malaria chemoprophylaxis with chloroquine within 5 months prior to the planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet® within 2 weeks prior to the challenge

• Any history of malaria

• Travel to a malaria endemic area within the previous 6 months

• Planned travel to malarious areas during the study period

• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products

• History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

• History of haemoglobinopathies

• History of diabetes mellitus

• Chronic or active neurological disease

• History of > 2 hospitalisations for invasive bacterial infections

• Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week

• Seropositive for hepatitis B surface antigen (HBsAg)

• Seropositive for hepatitis C virus (antibodies to HCV)

• Hepatomegaly, right upper quadrant abdominal pain or tenderness

• Evidence of serious psychiatric condition

• Any on-going chronic illness requiring hospital specialist supervision

• Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

• Pregnant or lactating woman

• Any woman who is willing or intends to become pregnant during the study

• Any history of anaphylaxis in reaction to vaccination

• Principal Investigator assessment of lack of willingness to participate and comply with all requirements of the protocol

• History or clinical evidence of intravenous drug abuse

• Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in this protocol

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Malaria
• Malaria, Falciparum

Intervention

Biological:
• PEV3A

• FP9 ME-TRAP

• MVA ME-TRAP

Locations

Country	Name	City	State
United Kingdom	Centre for Clinical Vaccinology and Tropical Medicine	Oxford	Oxfordshire

Sponsors (5)

Lead Sponsor	Collaborator
University of Oxford	Medical Research Council, Pevion Biotech Ltd, Swiss Tropical & Public Health Institute, Walter Reed Army Institute of Research (WRAIR)

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Vaccine efficacy: The primary outcome is protection against malaria infection in a P. falciparum sporozoite challenge model.
Secondary	Immunogenicity - Vaccine immunogenicity assessed by IFN-? ELISPOT and ELISA for vaccine specific antibodies
Secondary	Safety - Vaccine safety assessed by collection of local and systemic adverse events.